TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29917147
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) delivered house-to-house or at a central point, with or without compensation
Study: 29920582
Drug: Golimumab (GOL)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GOL) 200 mg at week 0, 100 mg at week 2, then 50 mg (<80 kg) or 100 mg (≥80 kg) every 4 weeks thereafter.
Study: 29921512
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg per day for 4 weeks in repeated 6-week cycles until disease progression or prohibitive toxicity
Study: 29921622
Drug: Ambulatory patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory patch ECG recorder (Zio XT monitor) fitted in the ED, continuously records a single-lead ECG for up to 14 days.
Study: 29921622
Drug: Ambulatory patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory patch ECG recorder (Zio XT monitor).
Study: 29921685
Drug: Combined optimisation
Normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined optimisation of general anaesthesia involving goal-directed haemodynamic therapy (GDHT), lung-protective ventilation (LPV), and electroencephalographic depth of anaesthesia monitoring (DAM)
Study: 29922050
Drug: Concurrent asthma
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent asthma diagnosis
Study: 29923063
Drug: Prophylactic scalp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic scalp cooling (PSC) with ELASTO-GEL hypothermia caps during adjuvant docetaxel treatment
Study: 29923063
Drug: Adjuvant docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant docetaxel (cumulative dose ≥ 400 mg/m²)
Study: 29923063
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving only endocrine therapy
Study: 29923931
Drug: Hypertonic lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic lactate (sodium lactate, 1,000 mmol/L; concentration, 30 µmol/kg/min) administered via three-hour IV infusion 39 hours from injury.
Study: 29924320
Drug: Soluble transferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble transferrin receptor
Study: 29925497
Drug: CCAT (computerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCAT (computerized cognitive addiction therapy) for 4 weeks plus regular detoxification treatment
Study: 29925497
Drug: Regular detoxification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular detoxification treatment as usual
Study: 29925549
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist (DA) use
Study: 29925549
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist (DA) discontinuation
Study: 29926288
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of plasma noradrenaline levels with norepinephrine dose
Study: 29926400
Drug: Ipragliflozin 50
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin 50 mg/day for 20 weeks, then 50 or 100 mg/day for 32 weeks
Study: 29926400
Drug: Ipragliflozin 100
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin 100 mg/day (for patients with insufficient control on 50 mg)
Study: 29926400
Drug: Ipragliflozin and
Normalized name: bexagliflozin
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin and GLP-1 receptor agonists/sulfonylureas
Study: 29926826
Drug: Control (extraventricular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (extraventricular drainage plus urokinase thrombolytic therapy)
Study: 29927704
Drug: 15 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 µg plague vaccine
Study: 29927704
Drug: 30 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 µg plague vaccine
Study: 29927782
Drug: Early-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-treatment group (15 months or less from diagnosis to cryoablation)
Study: 29927782
Drug: Late-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late-treatment group (greater than 15 months from diagnosis to cryoablation)
Study: 29927832
Drug: Mastectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mastectomy with temporizing implant, postmastectomy radiotherapy, and DIEP flap reconstruction
Study: 29927832
Drug: Immediate DIEP
Normalized name: limonene diepoxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate DIEP flap reconstruction or mastectomy with temporizing implant then DIEP flap surgery
Study: 29929092
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with doxorubicin (60 mg/m²) and ifosfamide for six cycles
Study: 29929092
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with doxorubicin and ifosfamide
Study: 29930021
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg (T90)
Study: 29930021
Drug: Ticagrelor 60
Normalized name: ticagrelor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 60 mg (T60)
Study: 29931068
Drug: 25-Hydroxyvitamin D
Normalized name: 25-hydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-Hydroxyvitamin D deficiency (<20 ng/mL)
Study: 29931068
Drug: 25-Hydroxyvitamin D
Normalized name: 25-hydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-Hydroxyvitamin D replete (≥30 ng/mL)
Study: 29932498
Drug: Structured light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured light plethysmography (SLP) before bronchodilator treatment
Study: 29932498
Drug: Structured light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured light plethysmography (SLP) after bronchodilator treatment
Study: 29933073
Drug: CC-486 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 (200 mg, n=3; 300 mg, n=4) once daily for 7 days per cycle
Study: 29933073
Drug: CC-486 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 (150 mg, n=4; 200 mg, n=19) for 14 days per cycle
Study: 29933073
Drug: CC-486 maintenance
Normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CC-486 maintenance therapy
Study: 29933095
Drug: Sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (400 mg orally, twice daily) combined with gemcitabine (1000 mg/m2) and cisplatin chemotherapy
Study: 29933272
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion at target plasma concentrations of 0.3, 0.6, 1.2, and 2.4 ng/mL
Study: 29934393
Drug: Concurrent HP-HD
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent HP-HD
Study: 29934393
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (HP, HD, concurrent HP-HD, Control)
Study: 29934438
Drug: LTA agonist
Normalized name: lidocaine hydrochloride Mucous Membrane Topical Solution [LTA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTA agonist and native LGG
Study: 29934438
Drug: CXCR4 agonist
Normalized name: CXCR4 INHIBITOR X4P-001
DrugBank: Mavorixafor (DB05501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXCR4 agonist
Study: 29934842
Drug: Permanent Iodine-125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permanent Iodine-125 Seed Implantation, median biologically effective dose (BED) about 180 Gy
Study: 29935143
Drug: Early capsule
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early capsule endoscopy
Study: 29936063
Drug: IMAB362 (Zolbetuximab)
Normalized name: immunoglobulin G1, anti-(human Claudin-18.2) (human-mus musculus monoclonal IMAB362 heavy chain), disulfide with human-mus musculus monoclonal IMAB362 .kappa.-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMAB362 (Zolbetuximab) 33, 100, 300, 600, and 1000 mg/m2 single dose
Study: 29936063
Drug: IMAB362 (Zolbetuximab)
Normalized name: immunoglobulin G1, anti-(human Claudin-18.2) (human-mus musculus monoclonal IMAB362 heavy chain), disulfide with human-mus musculus monoclonal IMAB362 .kappa.-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMAB362 (Zolbetuximab) 600 mg/m2 single dose
Study: 29936064
Drug: nab-paclitaxel 120
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 120 mg/m²
Study: 29936064
Drug: nab-paclitaxel 240
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 240 mg/m²
Study: 29936086
Drug: Prior diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior diabetes treatment assignment
Study: 29936438
Drug: TNFi monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFi monotherapy
Study: 29938772
Drug: Twice-weekly ixazomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly ixazomib 3·0 mg plus lenalidomide 25 mg and dexamethasone 20 mg (10 mg in cycles 9-16) for up to sixteen 21-day cycles, followed by maintenance with twice-weekly ixazomib alone.
Study: 29938772
Drug: Twice-weekly ixazomib-Rd
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly ixazomib-Rd
Study: 29938825
Drug: Cord blood
Normalized name: CORD BLOOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cord blood insulin
Study: 29940782
Drug: Stimulant medication
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant medication (single dose)
Study: 29942666
Drug: FOLFOX (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX (standard therapy)
Study: 29944518
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (IVI) treatment with ferric carboxymaltose (500-1000 mg)
Study: 29944518
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous iron (IVI) treatment
Study: 29944518
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (IVI) treatment
Study: 29944518
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (IVI) treatment and no IVI treatment
Study: 29945665
Drug: Formulations of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations of magnesium sulphate
Study: 29945738
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg/day) / Levocetirizine (5 mg/day)
Study: 29946005
Drug: Nintedanib added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib added to pirfenidone treatment
Study: 29946005
Drug: Pirfenidone (1602-2403
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone (1602-2403 mg·day)
Study: 29946013
Drug: Hemoglobin concentration
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin concentration >10 g/dL
Study: 29947745
Drug: Drug abuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug abuse in the family
Study: 29947806
Drug: Maternal serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal serum cobalamin concentration <394 pmol/L at week 18
Study: 29948356
Drug: Sonidegib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonidegib plus docetaxel (fixed dose at 75 mg/m2)
Study: 29948566
Drug: Once-daily PPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily PPI therapy
Study: 29948566
Drug: Twice-daily PPI
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily PPI therapy
Study: 29948566
Drug: Aspirin/NSAID use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin/NSAID use
Study: 29949102
Drug: Verinurad 15
Normalized name: Verinurad
DrugBank: Verinurad (DB11873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad 15 mg administered orally under fasted conditions
Study: 29950123
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C (Pascorbin®; Pascoe, Giessen, Germany)
Study: 29950463
Drug: ACL reconstruction
Normalized name: CONSTRICTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACL reconstruction (for participants who have surgical treatment)
Study: 29950465
Drug: Real-time audio-visual
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time audio-visual feedback on TSD to caregivers via premounted handhelds and tablets
Study: 29950475
Drug: Exenatide (add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (add-on treatment to insulin therapy)
Study: 29951694
Drug: Belinostat (48-h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belinostat (48-h continuous intravenous infusion)
Study: 29951694
Drug: Higher belinostat
Normalized name: Belinostat
DrugBank: Belinostat (DB05015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher belinostat drug exposure
Study: 29951694
Drug: q3week schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: q3week schedule of belinostat infusion
Study: 29951750
Drug: Multifaceted individualized
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted individualized pneumoperitoneum strategy (ventilation with low tidal volume, modified lithotomy position, deep neuromuscular blockade, pre-stretching of the abdominal wall, individualized intra-abdominal pressure titration)
Study: 29951977
Drug: Pregabalin (stepwise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (stepwise dose escalation from 75 mg to 600 mg daily)
Study: 29952895
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment (n = 6)
Study: 29953745
Drug: Muscle co-activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle co-activation strategies during activities of daily living
Study: 29954415
Drug: Bortezomib and
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib and rituximab maintenance therapy
Study: 29954418
Drug: search and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: search and destroy (SD) strategy, a quick and short, systemic antibiotic treatment
Study: 29954418
Drug: continuous suppression
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous suppression (CS) strategy, a repeated chronic topical antibiotic treatment
Study: 29954932
Drug: Ixazomib-melphalan-prednisone regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib-melphalan-prednisone regimen (ixazomib 4.0 mg [days 1, 8, 15] plus melphalan-prednisone 60 mg/m)
Study: 29954932
Drug: Single-agent ixazomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent ixazomib maintenance
Study: 29955707
Drug: Combined Carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Carbohydrate and Essential Amino Acid Supplement
Study: 29955710
Drug: Daily Ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily Ethanol Consumption
Study: 29955789
Drug: P4 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: P4 levels 60-100 nmol/l in early luteal phase
Study: 29955789
Drug: P4 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: P4 levels >400 nmol/l in early luteal phase
Study: 29955789
Drug: P4 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: P4 levels 150-250 nmol/l in mid-luteal phase
Study: 29955789
Drug: P4 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: P4 levels >400 nmol/l in mid-luteal phase
Study: 29955792
Drug: Tucatinib 300
Normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tucatinib 300 mg administered orally twice per day for 21 days and T-DM1 3.6 mg/kg administered intravenously once every 21 days.
Study: 29959809
Drug: Ceritinib (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceritinib (750 mg/day fasted)
Study: 29960116
Drug: Low-zinc group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-zinc group (zinc level <71 μg/dl)
Study: 29960116
Drug: Normal-zinc group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-zinc group (zinc level ≥71 μg/dl)
Study: 29960692
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of medication and CBT
Study: 29960692
Drug: Acute treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute treatment response
Study: 29961023
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training (IMT) using a tapered flow resistive loading device (POWERbreathe KH2, HaB International, UK), four sets of 6-10 breaths daily against an external load, adjusted to the highest tolerable load.
Study: 29961037
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 50 Allergan Units of botulinum toxin A (BTA) resuspended in 1 mL saline + splinting
Study: 29961037
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (1 mL) + splinting
Study: 29961037
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 50 Allergan Units of BTA + splinting
Study: 29961213
Drug: 35% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% hydrogen peroxide (HP) gel (control)
Study: 29961246
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin 0.3 U/kg (high dose corticosteroids group)
Study: 29961246
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin 0.15 U/kg (low dose corticosteroids group)
Study: 29961557
Drug: Cost drivers
Normalized name: river birch pollen extract
DrugBank: Betula nigra pollen (DB10458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost drivers associated with therapies received
Study: 29961557
Drug: Monthly direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly direct costs per patient during distant metastasis/terminal illness phase
Study: 29961557
Drug: Monthly direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly direct costs per patient during adjuvant treatment period
Study: 29962529
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of IV parecoxib
Study: 29962926
Drug: Carvedilol 12.5
Normalized name: carvedilol 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 12.5 mg single oral dose for 3 days, then 25 mg QD for 5 days, and 12.5 mg QD for another 3 days
Study: 29964145
Drug: In-person consultation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-person consultation at public events (e.g., basketball game, county fair)
Study: 29966800
Drug: Crizotinib 250
Normalized name: crizotinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib 250 mg orally twice daily continuously (3-week cycles)
Study: 29966800
Drug: Chemotherapy (pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (pemetrexed 500 mg/m2 intravenously)
Study: 29966863
Drug: Lobaplatin 25-50
Normalized name: Lobaplatin
DrugBank: Lobaplatin (DB13049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobaplatin 25-50 mg/m² concurrent with IMRT
Study: 29967693
Drug: Schizophrenia Coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schizophrenia Coping Oral Health Profile (SCOOHP)
Study: 29968431
Drug: Atorvastatin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin plus pioglitazone (30 mg/day)
Study: 29970005
Drug: Systematic medication
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic medication review based on the RASP list
Study: 29970319
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of soy-derived phosphatidic acid (PA)
Study: 29970357
Drug: Mobile phone
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile phone delivered intervention based on Acceptance and Commitment Therapy (ACT)
Study: 29970389
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injections on days 0, 30, 60, and 90, plus hyaluronic acid five times per day
Study: 29972089
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (FF/VI) 100[200]/25 µg
Study: 29972716
Drug: ASP8273 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP8273 300 mg
Study: 29973153
Drug: Phenylbutyrate (PBA)
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutyrate (PBA) 500mg twice daily for 8 weeks
Study: 29973204
Drug: Ipilimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (10 mg/kg IV every 3 weeks for 2 doses)
Study: 29973256
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 25% silver nitrate (AgNO3)
Study: 29975012
Drug: Patients without
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without widespread pain (WP) receiving biologic or conventional synthetic disease-modifying antirheumatic drugs (DMARDs)